Aripiprazole: Does partial dopaminergic agonism translate into clinical benefits?

M. Lynn Crismon; Anthony DeLeon; Alexander L. Miller

doi:10.1345/aph.1D014

Aripiprazole: Does partial dopaminergic agonism translate into clinical benefits?

M. Lynn Crismon, Anthony DeLeon, Alexander L. Miller

Department of Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Editorial › peer-review

12 Scopus citations

Original language	English (US)
Pages (from-to)	738-740
Number of pages	3
Journal	Annals of Pharmacotherapy
Volume	37
Issue number	5
DOIs	https://doi.org/10.1345/aph.1D014
State	Published - May 1 2003

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1345/aph.1D014

Cite this

@article{81c4fe3486c0426f896a8f0041cfd93f,

title = "Aripiprazole: Does partial dopaminergic agonism translate into clinical benefits?",

author = "Crismon, {M. Lynn} and Anthony DeLeon and Miller, {Alexander L.}",

year = "2003",

month = may,

day = "1",

doi = "10.1345/aph.1D014",

language = "English (US)",

volume = "37",

pages = "738--740",

journal = "Annals of Pharmacotherapy",

issn = "1060-0280",

publisher = "SAGE Publications Inc.",

number = "5",

}

TY - JOUR

T1 - Aripiprazole

T2 - Does partial dopaminergic agonism translate into clinical benefits?

AU - Crismon, M. Lynn

AU - DeLeon, Anthony

AU - Miller, Alexander L.

PY - 2003/5/1

Y1 - 2003/5/1

UR - http://www.scopus.com/inward/record.url?scp=0037407492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037407492&partnerID=8YFLogxK

U2 - 10.1345/aph.1D014

DO - 10.1345/aph.1D014

M3 - Editorial

C2 - 12708954

AN - SCOPUS:0037407492

SN - 1060-0280

VL - 37

SP - 738

EP - 740

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

IS - 5

ER -

Aripiprazole: Does partial dopaminergic agonism translate into clinical benefits?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this